Sphera Funds Management LTD. Decreases Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Sphera Funds Management LTD. trimmed its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 52.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,758 shares of the company’s stock after selling 129,893 shares during the period. Sphera Funds Management LTD. owned 0.28% of Kyverna Therapeutics worth $444,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Gilead Sciences Inc. purchased a new position in Kyverna Therapeutics during the fourth quarter valued at $15,432,000. Geode Capital Management LLC raised its position in shares of Kyverna Therapeutics by 21.7% in the fourth quarter. Geode Capital Management LLC now owns 539,682 shares of the company’s stock valued at $2,019,000 after buying an additional 96,370 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Kyverna Therapeutics by 2,225.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company’s stock valued at $1,728,000 after buying an additional 442,090 shares during the last quarter. Kera Capital Partners Inc. acquired a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at about $1,407,000. Finally, Integral Health Asset Management LLC raised its position in shares of Kyverna Therapeutics by 75.0% in the fourth quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company’s stock valued at $1,309,000 after buying an additional 150,000 shares during the last quarter. 18.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. HC Wainwright reduced their target price on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, April 3rd. Morgan Stanley reduced their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $18.33.

Kyverna Therapeutics Trading Up 1.4%

Kyverna Therapeutics stock opened at $2.18 on Friday. Kyverna Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $17.06. The stock has a market cap of $94.22 million, a P/E ratio of -0.63 and a beta of 2.17. The company has a 50-day moving average price of $2.15 and a 200 day moving average price of $3.30.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.18. As a group, analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.